Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

Posted: December 2, 2022 at 12:43 am

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will host a live webcast to review the Company’s clinical data on the AMELI-01 study (evaluating UCART123) presented at the ASH Annual Meeting, and provide a Company update, on December 13, 2022.

Originally posted here:
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

Related Posts